Below are the most recent publications written about "End Stage Liver Disease" by people in Profiles.
-
Kaplan A, Winters A, Klarman S, Kriss M, Hughes D, Sharma P, Asrani S, Hutchison A, Myoung P, Zaman A, Butler L, Pomposelli J, Gordon F, Duarte-Rojo A, Devuni D, Fortune B. The rising cost of liver transplantation in the United States. Liver Transpl. 2025 Sep 01; 31(9):1165-1175.
-
Bittermann T, Byhoff E. CON: Satellite clinics are a marketing tool and do not improve access and equity in liver transplantation. Liver Transpl. 2024 Oct 01; 30(10):1082-1085.
-
Sharma P, Shenoy A, Shroff H, Kwong A, Lim N, Pillai A, Devuni D, Haque LY, Balliet W, Serper M. Management of alcohol-associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities. Liver Transpl. 2024 Aug 01; 30(8):848-861.
-
Kanneganti M, Byhoff E, Serper M, Olthoff KM, Bittermann T. Neighborhood-level social determinants of health measures independently predict receipt of living donor liver transplantation in the United States. Liver Transpl. 2024 Jun 01; 30(6):618-627.
-
Kling CE, Biggins SW, Bambha KM, Feld LD, Perkins JH, Reyes JD, Perkins JD. Association of Body Surface Area With Access to Deceased Donor Liver Transplant and Novel Allocation Policies. JAMA Surg. 2023 06 01; 158(6):610-616.
-
Chuzi S, Tanaka Y, Bavishi A, Bruce M, Van Wagner LB, Wilcox JE, Ahmad FS, Ladner DP, Lagu T, Khan SS. Association Between End-Stage Liver Disease and Incident Heart Failure in an Integrated Health System. J Gen Intern Med. 2023 08; 38(11):2445-2452.
-
Vatsalya V, Feng W, Kong M, Hu H, Szabo G, McCullough A, Dasarathy S, Nagy LE, Radaeva S, Barton B, Mitchell M, McClain CJ. The Beneficial Effects of Lactobacillus GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis. Am J Gastroenterol. 2023 08 01; 118(8):1457-1460.
-
Hassanein T, McClain CJ, Vatsalya V, Stein LL, Flamm SL, Martin P, Cave MC, Mitchell M, Barton B, Nagy L, Szabo G, McCullough A, Dasarathy S, Shah J, Blevins C, Scott D, Krebs W, Brown JE, Lin W. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis. Am J Gastroenterol. 2024 01 01; 119(1):107-115.
-
Fundora Y, Hessheimer AJ, Del Prete L, Maroni L, Lanari J, Barrios O, Clarysse M, Gastaca M, Barrera G?mez M, Bonadona A, Janek J, Bosc? A, ?lamo Mart?nez JM, Zozaya G, L?pez Garnica D, Magistri P, Le?n F, Magini G, Patrono D, Nicovsk? J, Hakeem AR, Nadalin S, McCormack L, Palacios P, Zieniewicz K, Blanco G, Nu?o J, P?rez Saborido B, Echeverri J, Bynon JS, Martins PN, L?pez L?pez V, Dayangac M, Lodge JPA, Romagnoli R, Toso C, Santoyo J, Di Benedetto F, G?mez-Gavara C, Rotellar F, G?mez-Bravo M?, L?pez And?jar R, Girard E, Valdivieso A, Pirenne J, Llad? L, Germani G, Cescon M, Hashimoto K, Quintini C, Cillo U, Polak WG, Fondevila C. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis. J Hepatol. 2023 04; 78(4):794-804.
-
Szabo G, Mitchell M, McClain CJ, Dasarathy S, Barton B, McCullough AJ, Nagy LE, Kroll-Desrosiers A, Tornai D, Min HA, Radaeva S, Holbein MEB, Casey L, Cuthbert J. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology. 2022 10; 76(4):1058-1068.